Funded Startups in Blue Bell
Blue Bell, Pennsylvania shows a clear concentration in biotechnology among its recently funded companies.
Blue Bell, Pennsylvania shows a clear concentration in biotechnology among its recently funded companies. Three of the five listed — ThirdLaw Molecular, Seneca Therapeutics, and Automation & Validation Solutions — operate in the life sciences space, and both of the most recent rounds (closing in 2025) are in that sector. ThirdLaw Molecular raised a $6M Seed on October 10, 2025; Seneca Therapeutics closed a $4M Series B on August 28, 2025.
The remaining two companies represent different verticals: BuildED (education) raised $600K in a Series Unknown round in January 2024, and Gen3 Marketing (advertising) received a $100K Private Equity investment in September 2021. Among the five rounds, disclosed amounts range from $100K to $6M, with one undisclosed private equity transaction from Automation & Validation Solutions in October 2022. Round types span Seed, Series B, and private equity, reflecting a mix of early-stage and growth-oriented capital events.
Most recent rounds
5 shownRelated listings
Frequently asked
What is the largest disclosed round among recently funded Blue Bell companies?
ThirdLaw Molecular leads with a $6M Seed round closed October 10, 2025. Seneca Therapeutics is the next largest at $4M in a Series B closed August 28, 2025. Both are biotechnology companies.
Which sector accounts for most of the funded companies in Blue Bell?
Biotechnology accounts for three of the five listed companies: ThirdLaw Molecular, Seneca Therapeutics, and Automation & Validation Solutions. The remaining two operate in education (BuildED) and advertising (Gen3 Marketing).
What round stages show up in Blue Bell's recent funding data?
The five rounds include Seed, Series B, Private Equity (two instances), and one round classified as Series Unknown. There are no Series A rounds in the current dataset.
How active has Blue Bell been in terms of funding timing?
Two rounds closed in 2025 — both in the second half of the year — making them the most recent activity. One round dates to January 2024, one to October 2022, and the earliest is September 2021. The cluster of 2025 activity is driven entirely by biotech.
Are any of the Blue Bell rounds undisclosed in size?
Yes, Automation & Validation Solutions' Private Equity round from October 18, 2022 has no disclosed amount. The other four rounds all have disclosed figures, ranging from $100K to $6M.
Is there any early-stage (pre-Series A) activity among Blue Bell's listed funded companies?
ThirdLaw Molecular's $6M Seed round (October 2025) is the only explicitly early-stage round in the dataset. BuildED's $600K round is classified as Series Unknown, so its stage cannot be confirmed from the available data.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.